热门资讯> 正文
Equillium股价因RA Capital Management 3500万美元融资而上涨
2026-03-13 20:20
- Equillium (EQ) shares rose 13% premarket after the biotechnology firm secured about $35M in new financing to advance its clinical development of EQ504, an investigational AhR modulator intended to treat ulcerative colitis locally.
- Pursuant to a securities purchase agreement with RA Capital Management, the company will issue around 18.9M shares of its common stock (including shares of common stock underlying pre-funded warrants), representing a purchase price of $1.854 for each share of common stock.
- Equillium intends to use the net proceeds from the financing for further advancement of EQ504, working capital, and general corporate purposes.
- The anticipated net proceeds, along with existing cash and cash equivalents, are expected to extend the cash runway into 2029.
More on Equillium
- Equillium: Multi-Cytokine Platform To Go Beyond Scope Of EQ504 For UC
- Seeking Alpha’s Quant Rating on Equillium
- Historical earnings data for Equillium
- Financial information for Equillium
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
